RAPP

Rapport Therapeutics

RAPP

Market cap $1.14B

Overview Fund Activity

24.73 USD

+0.97

4.08%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

25.38

+0.65

2.63%

1 day

4.08%

5 days

-22.53%

1 month

68.12%

3 months

120.8%

6 months

142.93%

Year to date

34.48%

1 year

31.61%

5 years

18.89%

10 years

18.89%

About: Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Employees: 69

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

15% more capital invested

Capital invested by funds: $382M [Q1] → $438M (+$55.6M) [Q2]

5% more funds holding

Funds holding: 77 [Q1] → 81 (+4) [Q2]

1.08% more ownership

Funds ownership: 104.39% [Q1] → 105.47% (+1.08%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $10K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$28

13% upside

Avg. target

$31

25% upside

High target

$34

37% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Douglas Tsao	$34	Buy Maintained	8 Sep 2025
JMP Securities Jason Butler	$28	Market Outperform Reiterated	8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about RAPP published over the past 30 days

Zacks Investment Research

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal

Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025

Crédit Agricole Normandie Seine : Rapport financier semestriel 2025 Le rapport financier semestriel au 30/06/2025 de la Caisse régionale de Crédit Agricole Mutuel Normandie Seine a été déposé auprès de l'Autorité des Marchés Financiers (AMF). Ce rapport comprend les éléments suivants : Examen de la situation financière et résultats Informations prudentielles et facteurs de risques Présentation des comptes consolidés Rapport des Commissaires aux Comptes sur les comptes consolidés Attestation du responsable de l'information financière Ce document en version française est consultable sur le site Internet du Crédit Agricole Normandie Seine : rubrique "Informations réglementées" ou sur le lien suivant : https://www.credit-agricole.fr/ca-normandie-seine/particulier/informations/informations-reglementees-maj.html Attachment 04.C1 - CR883 - Rapport Word - Groupe C Semestriel_Vdef

Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference.

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Rapport stock plunges 18% on Wednesday: what went wrong after 200% rally

Rapport stock (NASDAQ: RAPP) cratered 18% on Wednesday as the market delivered a harsh verdict on its latest funding strategy. The catalyst was as predictable as it was painful.

Rapport stock plunges 18% on Wednesday: what went wrong after 200% rally

Rapport Announces Pricing of Public Offering of Common Stock

BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share.

Rapport Announces Pricing of Public Offering of Common Stock

Rapport Announces Proposed Public Offering of Common Stock

BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Rapport. In addition, Rapport intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rapport Announces Proposed Public Offering of Common Stock

Rapport stock rockets nearly 200% today, but analysts warn of possible crash soon

Rapport stock (NASDAQ: RAPP) exploded on Monday, climbing nearly 200% in just one trading session. The jump came after a mix of excitement over upcoming clinical trial data and growing confidence that this small but ambitious company might be onto something big.

Rapport stock rockets nearly 200% today, but analysts warn of possible crash soon

Investors Business Daily

Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures

Rapport Therapeutics stock catapulted Monday after its drug reduced seizures in patients with a hard-to-treat form of epilepsy.

Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for the 8-week treatment period (p

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025

See News Rankings

Charts implemented using Lightweight Charts™